Key Performance
More- Earnings Score: 31
- Momentum Score: 37
- True Yield: 58
- Financial Health Score: 35
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America leads the market while Asia-Pacific is positioned for rapid expansion.
07/13/2026, 7:32 AM • GlobeNewswire
Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGR
The global environmental DNA (eDNA) market is expected to grow at a CAGR of 10.2% from 2026 to 2031, driven by non-invasive species detection methods, stricter environmental regulations, and increasing demand for ecosystem health monitoring. North America leads the market with advanced research infrastructure and strong public-private collaborations, while air sampling and climate change impact assessment segments show particularly strong growth potential.
07/06/2026, 4:49 AM • GlobeNewswire
The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and Europe $19.32 billion by 2035, with Asia-Pacific showing the fastest growth.
07/03/2026, 6:48 AM • GlobeNewswire
The global single-use bioreactors market is projected to experience robust growth with a CAGR of 17.27%, expanding from USD 3.61 billion in 2025 to USD 15.11 billion by 2034. Growth is driven by increasing biopharmaceutical demand, cost efficiency advantages, and technological advancements in bioprocessing. North America is expected to dominate, while Asia-Pacific shows rapid expansion. Major players include Sartorius, Thermo Fisher Scientific, and Cytiva, with recent developments including new product launches and facility expansions.
07/03/2026, 5:12 AM • GlobeNewswire
Sweden's flu diagnostic and treatment market is projected to grow from USD 172.1 million in 2026 to USD 210.3 million by 2031 at a 4.1% CAGR, driven by high influenza burden among elderly populations and increased adoption of molecular diagnostics and targeted antiviral therapies. The market operates within Sweden's centralized healthcare system with key players including Roche, Thermo Fisher Scientific, 3M, and Meridian Bioscience, though growth is constrained by seasonality, regulatory compliance requirements, and supply chain vulnerabilities.
07/03/2026, 4:47 AM • GlobeNewswire
Global Pharmaceutical Filtration Market to Double by 2034: Insights on Driving Factors
The global pharmaceutical filtration market is expected to grow at a CAGR of 8.13% from 2025 to 2034, driven by rising biopharmaceutical demand, CDMO expansion, and increased sterile drug manufacturing. North America leads the market, while Asia-Pacific emerges as a rapidly growing region. Major players are investing in capacity expansion and acquisitions to meet growing demand, though high operational costs and filter clogging challenges persist.
07/03/2026, 4:43 AM • GlobeNewswire
The global sterile bioprocess filtration market is projected to grow from USD 6.50 billion in 2025 to USD 31.33 billion by 2034, at a CAGR of 19.13%. Growth is driven by rising biopharmaceutical and vaccine demand, outsourcing to CMOs/CDMOs, and technological advancements. North America is expected to lead the market, with membrane filters dominating the product segment.
07/03/2026, 4:42 AM • GlobeNewswire
The CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.
07/03/2026, 4:41 AM • GlobeNewswire
Oxidative Stress Assay Market Size to Reach USD 3.25 Billion by 2035 | SNS Insider
The global Oxidative Stress Assay Market is projected to grow at a CAGR of 9.53% from 2026 to 2035, driven by rising chronic disease prevalence, pharmaceutical R&D investments, and advancements in biomarker diagnostics. North America leads with 38.52% market share, while Asia-Pacific is expected to show the highest growth rate at 10.55%. ELISA technology dominates with 39% market share, and cancer research accounts for 33% of revenue.
06/28/2026, 10:30 PM • GlobeNewswire
The global LIMS market is projected to grow from USD 2.88 billion in 2025 to USD 5.19 billion by 2030, with a CAGR of 12.5%. Growth is driven by increasing demand for laboratory automation, regulatory compliance, cloud-based solutions, and AI integration. North America leads the market, while large enterprises dominate adoption. Key challenges include high maintenance costs and system integration complexities.
06/26/2026, 11:00 AM • GlobeNewswire
Bloodstream Infection Testing Market Size to Reach USD 1,404.68 Million by 2035 | SNS Insider
The global bloodstream infection testing market is expected to grow at a CAGR of 4.80% through 2035, driven by rising sepsis cases, antimicrobial stewardship mandates, and adoption of rapid molecular diagnostics. North America leads the market, with the U.S. contributing 87.4% of regional revenues, while Asia Pacific shows the fastest growth. Key technologies include molecular diagnostics and whole blood testing, which are rapidly replacing traditional blood culture methods.
06/26/2026, 4:30 AM • GlobeNewswire
The global laboratory equipment services market is projected to grow from USD 28.94 billion in 2025 to USD 62.83 billion by 2035, at a CAGR of 8%. Growth is driven by increased R&D investments in life sciences, stricter regulatory compliance requirements, expansion of biopharma facilities, and adoption of IoT-enhanced predictive maintenance technologies. Repair and maintenance services represent the largest market segment, with North America dominating and Asia Pacific showing the fastest growth.
06/24/2026, 3:30 PM • GlobeNewswire
Enteric Disease Testing Market Worth USD 5.86 Billion by 2035 | SNS Insider
The global Enteric Disease Testing Market is valued at USD 4.08 billion in 2025 and is projected to reach USD 5.86 billion by 2035, growing at a CAGR of 3.70%. Growth is driven by increasing foodborne and waterborne disease prevalence, rising demand for rapid pathogen detection, and expanding adoption of multiplex molecular diagnostics. North America and Europe are leading markets, with Asia-Pacific emerging as the fastest-growing region.
06/23/2026, 4:35 AM • GlobeNewswire
The global decentralized clinical trials market is projected to grow from USD 9.9 billion in 2025 to USD 38.3 billion by 2035, at a CAGR of 14.5%. Growth is driven by digital health technologies, remote patient engagement, and ecosystem expansion involving CROs and platform vendors. Oncology represents the largest therapeutic segment at 45% market share, while pharmaceutical and biotech sponsors lead end-user adoption at 55% market share. North America currently dominates, while Asia-Pacific shows the fastest growth.
06/22/2026, 3:30 PM • GlobeNewswire
The global dimethylformamide (DMF) market is projected to grow from USD 2.79 billion in 2025 to USD 4.54 billion by 2035, at a CAGR of 4.98%. Growth is driven by pharmaceutical API manufacturing expansion in India and China, synthetic leather production in Asia Pacific, and electronics-grade DMF demand. Industrial grade dominates with 58.4% market share, while pharmaceutical grade is the fastest-growing segment at 7.9% CAGR. North America leads with 38.9% revenue share, while Europe faces REACH regulatory compliance pressures.
06/20/2026, 5:30 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 07/10/2026
Company Profile
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.